MADRIGAL PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of -$9.95 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2025-02-26
- MADRIGAL PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was -$9.95M.
- MADRIGAL PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was -$8.29M.
- MADRIGAL PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was -$7.84M.
- MADRIGAL PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2021 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | -$9.95M 10-K · filed 2025-02-26 | |
| 2023-12-31 | -$8.29M 10-K · filed 2025-02-26 | |
| 2022-12-31 | -$7.84M 10-K · filed 2025-02-26 | |
| 2021-12-31 | $0.00 10-K · filed 2024-02-28 | |
| 2020-12-31 | -$47.00K 10-K/A · filed 2023-03-03 | -$68.00K 10-K · filed 2021-02-25 |
| 2019-12-31 | -$47.00K 10-K · filed 2022-02-24 | |
| 2018-12-31 | -$3.42M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $138.00K 10-K · filed 2020-02-26 | |
| 2016-12-31 | $407.00K 10-K · filed 2019-02-27 | |
| 2015-12-31 | $1.23M 10-K · filed 2016-03-15 | |
| 2014-12-31 | $1.09M 10-K · filed 2016-03-15 | |
| 2013-12-31 | $1.12M 10-K · filed 2016-03-15 | |
| 2012-12-31 | $382.00K 10-K · filed 2015-03-12 | |
| 2011-12-31 | $373.00K 10-K · filed 2014-03-11 | |
| 2010-12-31 | $791.00K 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |